Relevant Concepts of the Development Mechanisms, Systematization, and Therapeutic-Associated Risk Factors of Momentary Cancer

Karimova Mavluda Nigmatovna; Nizomitdinova Zinura Isomiddinovna; Rakhimova Madinabonu Ulmas kizi

Authors

Karimova Mavluda Nigmatovna DSc. Oncology Department Samarkand State Medical University
Nizomitdinova Zinura Isomiddinovna Resident of the master's program of the Department of Oncology Samarkand State Medical University
Rakhimova Madinabonu Ulmas kizi Resident of the Master's Program of the Department of Oncology Samarkand State Medical University

Keywords:

lymphedema, breast cancer, axillary lymph node dissection, radiotherapy, risk factors, quality of life

Abstract

Breast cancer is one of the most pressing problems in modern oncology, occupying a leading position in the structure of oncological morbidity among women worldwide and accounting for approximately 30% of all malignant neoplasms in women. According to the World Health Organization, more than 2.3 million new cases of breast cancer are registered annually worldwide, making this disease a global public health problem requiring a comprehensive interdisciplinary approach to its study, diagnosis, and treatment.

References

1. Harbeck, N., Penault-Llorca, F., Cortes, J., et al. (2019). Breast cancer. Nature Reviews Disease Primers, 5(1), 66. doi:10.1038/s41572-019-0111-2

2. Perou, C.M., Sørlie, T., Eisen, M.B., et al. (2020). Molecular portraits of human breast tumours revisited: insights from the genomic era. Nature Reviews Cancer, 20(8), 420-434. doi:10.1038/s41568-020-0262-3

3. Cardoso, F., Kyriakides, S., Ohno, S., et al. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 30(8), 1194-1220. doi:10.1093/annonc/mdz173

4. André, F., Ciruelos, E., Rubovszky, G., et al. (2021). Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. New England Journal of Medicine, 380(20), 1929-1940. doi:10.1056/NEJMoa1813904

5. Kuchenbaecker, K.B., Hopper, J.L., Barnes, D.R., et al. (2019). Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA, 317(23), 2402-2416. doi:10.1001/jama.2017.7112

6. M. N. Karimova, I. G. Nurmamedova, T. A. Rizayev Hormone therapy in the treatment of metastatic breast cancer Doctor's information No 2 (119) - 2025; 161-166.

7. M. N. Karimova, A. F. Asatulaev, K. A. Rakhmonov, I. G. Nurmamedova Gestational gigantomastia Doctor's Information No. 2 (119) - 2025; 167-170.

8. 3.M. N. Karimova, K. A. Rahmonov, I. G. Nurmamedova JUVENILE MACROMASTY Doctoral Information No. 3 (120) - 2025; 129-133.

9. Early Breast Cancer Trialists' Collaborative Group. (2020). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 379(9814), 432-444. doi:10.1016/S0140-6736(11)61625-5

10. Robson, M., Im, S.A., Senkus, E., et al. (2019). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377(6), 523-533. doi:10.1056/NEJMoa1706450

11. Liedtke, C., Mazouni, C., Hess, K.R., et al. (2018). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology, 26(8), 1275-1281. doi:10.1200/JCO.2007.14.4147

12. Sparano, J.A., Gray, R.J., Makower, D.F., et al. (2020). Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. New England Journal of Medicine, 379(2), 111-121. doi:10.1056/NEJMoa1804710

13. Slamon, D.J., Leyland-Jones, B., Shak, S., et al. (2019). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344(11), 783-792. doi:10.1056/NEJM200103153441101